Le Lézard
Classified in: Health
Subject: PLW

Bioretec's hybrid composite patent has been approved in Europe


Bioretec Ltd Company announcement 8 September 2022 at 5.00 p.m. EET

TAMPERE, Finland, Sept. 8, 2022 /PRNewswire/ -- The European Patent Office has announced to approve Bioretec Oy's hybrid composite material patent application EP3782657A1 and will grant and publish the patent after the Company's confirmation.

Approved patent concerns magnesium-based reinforced composite material, i.e., hybrid composite. The patent also includes the usage of the hybrid composite material in the manufacturing of a medical device or a part of such a device.

The patented hybrid composite material will be used in those products of Bioretec's RemeOstm product family that require very high load-bearing capacity. Targeted applications include intramedullary nails in the long bones of the upper and lower extremities and implants for spinal fusion. The hybrid composite material biodegrades in the body similarly as the RemeOstm magnesium alloy material and is replaced by bone while promoting fracture healing, thus eliminating the need for implant removal surgery.

The patent application process for the hybrid composite material in regions outside of Europe continues based on the international PCT patent application WO2021032882A1 and the Company will inform about patent approvals in other regions as the application process progress.

Further enquiries

Timo Lehtonen, CEO, p. +358 50 433 8493
Johanna Salko, CFO, p. +358 40 754 8172

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of bioresorbable orthopedic implants. The company has built unique competencies in the?biological interface?of active implants?to enhance bone growth and accelerate fracture healing after orthopedic surgery. ?The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.?

Bioretec is?developing?the new RemeOstm?product line?based on a magnesium alloy and hybrid composite, introducing a new generation of strong bioresorbable materials for enhanced surgical outcomes. The RemeOstm implants are resorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on?value for patients through efficient healthcare. With the U.S. and EU market authorization for the first RemeOstm product expected in 2022, Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical possibilities.

Better Healing - Better Life. www.bioretec.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioretec/r/bioretec-s-hybrid-composite-patent-has-been-approved-in-europe,c3628173

 

SOURCE Bioretec


These press releases may also interest you

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...



News published on and distributed by: